IntroductIon
environmental changes, leishmaniasis is spreading to nonendemic areas of the world.
at present, no vaccine against Leishmania infection is available. current treatment is based on chemotherapy using a few drugs that are limited by inconsistent efficacy and many side effects. pentavalent antimonials (sodium stibogluconate, meglumine antimoniate) have been the first-line treatment for 60 years. Other drugs such as pentamidine, paromomycin, and amphotericin B (amB) are second-line treatment. miltefosine, sitamaqine, imiquimod, and several azoles (ketoconazole, fluconazole, and itraconazole) are currently under clinical trials. cost issues, variable Leishmania species sensitivity, toxicity, and pharmacokinetic variation underline the urgent need for developing new, effective, and affordable therapies to control the disease (http:// www.who.int/tdr/diseases/leish/diseaseinfo.htm).
protein disulfide isomerase (pdi, ec 5.3.4.1) belongs to the thioredoxin superfamily. it is an endoplasmic reticulum-located protein and is expressed at high levels in the endoplasmic reticulum of eukaryotic cells. pdi is a multifunctional protein able to catalyze disulfide bond formation (oxidation), breakage (reduction), and rearrangement (isomerization) in nonnative protein and peptide substrates via its two cGhc active sites present in a and a′ domains. in addition, pdi displays chaperone and antichaperone activities.
1,2 pdi has been involved in several virulence functions in both prokaryotic and eukaryotic pathogens. For example, dsba (a bacterial homologue of pdi) is involved in the biogenesis of the enterotoxin and toxin-coregulated pili of Vibrio cholerae.
3 in addition, it was shown that pdi plays a major role in assisting the folding of various secretory proteins implicated in virulence mechanisms of intracellular pathogens such as Neospora caninum. 4 the involvement of pdi in such functions makes it an interesting drug target. its enzymatic activities are well studied, and various in vitro assays have been developed to measure reductase, isomerase, and chaperone activities. 1 however, at present, only the reductase activity has been adapted to high-throughput screening (hts). in 2004, smith and coworkers 2 developed an insulin reduction-based hts assay for bovine liver pdi.
Ben achour and coworkers 5 identified a 52-kda pdi in Leishmania major protein disulfide isomerase (Lmpdi). the protein was shown to be overexpressed in high-virulence isolates and secreted by the parasite. 6 Lmpdi inhibitors affected parasite growth in vitro, 5 and amastigote proliferation in infected macrophages 7 and gene deletion abolished parasite infectivity in BaLB/c mice (unpublished data). Lmpdi enzymatic activities have been characterized and assays for reductase and chaperone activities developed in a 96-well format for the screening of inhibitors. 7 in this study, we set a highly sensitive 384-well plate turbidometric endpoint assay for insulin reduction based on the work by smith et al., 2 which can be readily adapted to automated hts of large chemical libraries to identify Lmpdi inhibitors. We used this assay to screen a small library consisting of 1920 bioactive synthetic and natural compounds and found 27 compounds with inhibitory activity against Lmpdi. these compounds were further tested for cytotoxicity evaluation in Jurkat cells and activity against Leishmania donovani amastigotes using high-content analysis.
mAterIALS And metHodS

Chemical library
the microsource spectrum library is a collection of 1995 compounds, including drugs approved for human use, compounds with known biological activities, and natural products obtained from microsource discovery systems, inc. (Gaylordsville, ct). the composition of the library is available at http://www.msdiscovery.com/spectrum.html.
LmPDI HTS assay
a high-throughput screen was conducted to identify leadlike compounds that inhibited Lmpdi reductase activity. this method is based on the direct measurement of the turbidity of precipitated free a and B chains produced by reduction of insulin interchain disulfide bonds by pdi. 8 recombinant Lmpdi was expressed as a 6-his tagged protein in a BL21(de3) pLyss Escherichia coli strain as previously described. 5 purification of the fusion protein was performed by affinity chromatography over ni-nta resin using imidazole gradient elution according to the manufacturer's recommendation (Ge healthcare, Biosciences, Uppsala, sweden). purity was demonstrated by 12% sodium dodecyl sulfate (sds) polyacrylamide gel electrophoresis (paGe) and coomassie blue staining.
Assay setup
the assay was first performed in clear-bottom 96-well plates (nunc, rochester, nY) in a total reaction volume of 100 µL and a final concentration of 1.25 µm of Lmpdi as described previously. 7 hydrogen peroxide (230 mm) was used as a stop reagent. 
HTS-turbidometric assay
the assay mixture was then prepared in clear-bottom 384-well plates (Greiner Bio One, monroe, nc) in a total reaction volume of 50 µL. recombinant Lmpdi was diluted to a final concentration of 1.25 µm in 0.1 m potassium phosphate, 2 mm edta, and 0.33 µm dithiothreitol (dtt; ph 7) to a final volume of 40 µL. then, 1920 compounds from microsource's library, dissolved in dmsO, were added (n = 1) so that final concentration of dmsO and compounds was 2% and 20 µm, respectively. We previously showed that up to 2% dmsO had no effect on the rate of reaction. 7 plates were then incubated for 10 min at room temperature. the reaction was started by adding 10 µL of insulin (sigma, st. Louis, mO; 0.348 mm) prepared in 50 mm tris-hcl (ph 8) in all wells. after 30 min at room temperature, reactions were stopped by adding h 2 O 2 (230 mm). the enzymatic reduction of insulin was measured at 650 nm using a spectrophotometer (spectramax m5, molecular devices, sunnyvale, ca). in all plates, the 0% inhibition control wells contained 2% dmsO (n = 32), and the 100% inhibition wells contained 200 µm bacitracin (n = 16). percent enzyme inhibition was calculated using the following formula:
where Od compound , Od control , and Od vehicle are Od 650 values of wells containing compound, bacitracin, and dmsO, respectively. "hits" were selected as compounds that inhibited more than the mean inhibition of all the compounds plus 3 sd (43%). For each plate, Z′ factor was determined according to Zhang et al. Dose-response determination selected compounds were then picked from a fresh 10-mm copy of the library. compounds were diluted 1:3 in dmsO and added to the enzymatic assay in the same manner as the primary screen at final concentrations ranging from 100 to 3.7 µm (n = 1). raw values were converted to log 10 , and ic 50 curve fittings were performed with Graphpad prism 4 software (Graphpad software, san diego, ca).
Cytotoxicity assay
cytotoxicity evaluation of the selected compounds was performed using the Jurkat cell assay. Viability of Jurkat cells (transformed human leukemia t cells) was measured using a luciferase-coupled adenosine triphosphate (atp) quantitation assay, where the luminescent signal is proportional to the amount of atp and thus to the number of metabolically competent cells; cell injury and death result in a dramatic decrease in intracellular atp levels.
Jurkat cells (clone e6-1) were grown in complete rpmi-1640 medium containing 10% fetal bovine serum (FBs), 50 U/mL penicillin, and 50 µg/mL streptomycin (invitrogen, carlsbad, ca) at 37 °c under a humidified atmosphere and 5% cO 2 .
For cytotoxicity testing, cells were diluted to 10 5 per milliliter in complete rpmi-1640 medium. test compound stocks were prepared in 100% dmsO and serially diluted to the desired concentration series. then, 1 µL of each dilution was added to 99 µL of diluted cells (1 × 10 4 cells per well) in sterile Greiner 96-well flat white opaque culture plates such that the final dmsO concentration was 0.5%. negative control (0% inhibition, n = 8) wells contained 0.5% dmsO, whereas positive control (100% inhibition, n = 8) wells contained 40 µm staurosporine. after compound addition, plates were incubated for 40 h at 37 °c. dose-response curves of staurosporine were performed in parallel for quality control with concentration ranging from 0.5 nm to 40 µm.
at the end of the incubation period, 50 µL of celltiter-Glo reagent (promega, madison, Wi) was added to each well, and plates were placed on an orbital shaker at room temperature for 10 min to induce lysis. after 10-min incubation to stabilize the signal, the atp-bioluminescence of each well was determined using an analyst ht plate reader (molecular devices). percent growth inhibition was calculated using the following formula:
where raw compound , raw control , and raw vehicle are luminescence values of wells containing compound, staurosporine, and dmsO, respectively. raw values were converted to log 10 , and ic 50 curve fittings were performed with Graphpad prism 4 software (Graphpad software).
Determination of in vitro activity of compounds against L. donovani intracellular amastigotes
L. donovani promastigotes (strain 1s, clone 2d [mhOm/ sd/62/1s-cl2d]) were grown at 27 °c in rpmi supplemented with 10% fetal calf serum (Fcs) and 10% brain heart tryptose (Bht). promastigotes were grown to a stationary phase prior to each experiment.
thp-1 cells (human acute monocytic leukemia cell lineatcc tiB202) were grown in rpmi supplemented with 10% Fcs and 50 mm β-mercaptoethanol at 37 °c in 5% cO 2 . maturation of adherent macrophages was achieved by treating exponentially growing cultures (5.10 5 /mL) with 0.1 µm phorbol myristate acetate (pma; sigma) at 37 °c for 48 h.
after activation by pma, cells were resuspended in complete rpmi medium containing stationary phase L. donovani promastigotes at a macrophage/promastigote ratio of 1:20. after a 6-h incubation at 37 °c, noninternalized promastigotes were removed by two to three successive washes, and fresh medium containing test compounds, positive control (2 µm amB), or negative control (1% dmsO) was added. For ec 50 determinations, compounds were serially diluted twofold in dmsO, with final assay concentrations ranging from 0.62 to 20 µm. cultures were incubated at 37 °c for 72 h. cells were fixed with 4% formaldehyde and stained with 4′,6′-diamidino-2-phenylindole (dapi) 300 nm. images were acquired with an in cell analyser 1000 (Ge healthcare). host cell nuclei and parasite kinetoplasts were counted, and the amount of parasites/host cell was determined for each well. parasite growth inhibition was determined for each well based on parasite/host cell values for negative (dmsO) and positive (amB) controls. ec 50 curve fitting was carried out using Graphpad prism 4 software (Graphpad software).
cytotoxicity of compounds on thp-1 cells was evaluated in the absence of parasites. cells were incubated in the presence of compound concentrations ranging from 0.62 to 20 µm and were counted as described.
Statistical analysis
statistical analyses were performed using the Graphpad instat software version 3.06 for Windows (Graphpad software). all data comparisons were tested for significance by means of the one-way analysis of variance (anOVa) using the Bonferroni posttest for multiple comparisons of groups. P values <0.05 were considered statistically significant.
reSuLtS And dIScuSSIon
intra-and interchain disulfide bond formation is a critical process for the correct folding and stabilization of cysteinecontaining proteins, many of which are secreted or intramembrane proteins. For several pathogens, those proteins play a major role in host-cell interactions and virulence mechanisms. in Plasmodium falciparum, for example, it was shown that many proteins containing conserved cysteines need correct disulfide linkage for their biological activity that contribute to the pathogenesis and virulence of the parasite.
10 major immunodominant surface antigens of N. caninum and secreted proteins involved in adhesive/invasive properties of the parasite exhibit a high number of disulfide bridges. 4 hence, targeting enzymes involved in thiol metabolism could be a promising area for development of new antileishmanial chemotherapies.
We have previously shown that Lmpdi, a 52-kda Lmpdi, displays the characteristic activities of the pdi protein family: oxidoreductase, isomerase, and chaperone. 1 Lmpdi is both an intracellular and secreted protein of the parasite. 6 the protein sequence is well conserved among Leishmania species (97% homology with L. donovani) and divergent from the human enzyme (33% of homology). specific inhibitors for both chaperone and reductase activities are able to inhibit extracellular promastigote (L. major) and intracellular amastigote (L. donovani) proliferation in vitro. 7 the lmpdi gene deletion did not affect promastigote viability in vitro but abolished parasite infectivity in BaLB/c mice (unpublished data), implying that the gene is essential for survival in the mammalian host. these data suggest that Lmpdi could constitute a valid and promising drug target for antileishmanial chemotherapy. in addition, the role of the host macrophage pdi in Leishmania phagocytosis has been shown recently. indeed, preincubation of macrophages with pdi inhibitors partially blocks Leishmania macrophage phagocytosis and therefore the infectivity. 11 to date, however, only one study has described the use of hts technology for identifying inhibitors of bovine liver pdi. 2 We have previously characterized the enzymatic activities of Lmpdi. 7 the recombinant protein was able to reduce the disulfide linkage between chains of insulin, causing its precipitation and resulting in a rise of turbidity measured at 650 nm. a 96-well plate format assay was set up, and the optimal concentration of Lmpdi was shown to be 1.25 µm. the assay tolerates up to 2% dmsO, 7 with inhibition at higher concentrations being most likely due to dissolution of insulin aggregates rather than enzyme sensitivity.
2 to adapt the assay for hts, we had to resolve two major challenges. First, the assay had to be reproducible and show a good signal-to-background ratio. For assay validation, three experiments were carried out in the presence or absence of 1.25 µm Lmpdi, and Od 650 was measured every 24 s. reactions in the three experiments started 10 min after insulin addition, and the signal was linear and showed good reproducibility (p < 0.05) for more than 20 min ( fig. 1A) . the enzyme reaction rate was 0.011 ± 10 −4 Od 650 unit/min with a high signal-to-background ratio of 6.75 ± 0.11 at 30 min of reaction. second, to be formatted to an endpoint assay, the reaction had to be stopped without any disturbance of the precipitate. h 2 O 2 was shown to be an efficient stop reagent, 2 and we demonstrated that with 230 mm peroxide, the reaction was stopped immediately, and the signal stayed constant at Od 650 = 0.332 for more than 20 min ( fig. 1B) compared to the reaction without peroxide addition.
We then adapted our assay to a 384-well format in a final volume of 50 µL for the hts of 1920 compounds from the microsource spectrum Library. screening was run in 1 day in six plates with a compound concentration of 20 µm and a final dmsO concentration of 2%. Bacitracin at 200 µm served as a positive control of inhibition. the primary screen identified 29 compounds that inhibited the reductase activity of Lmpdi by more than 43% ( fig. 2) , yielding a hit rate of 1.5% at a compound concentration of 20 µm. the average Z′ factor for the six plates was 0.78 ± 0.06, demonstrating the robustness of the developed assay format. hit confirmation was conducted by dose-response curve determination. selected compounds were then picked from a fresh 10-mm copy of the library for conducting dose-response curves in the same manner as the primary assay. two compounds displayed no inhibition (ic 50 > 100 µm) and were considered false hits, yielding a hit confirmation rate of 93.1%. From the selected hits, 48% had an ic 50 lower than 10 µm (table 1) . these data confirmed that our hts assay conditions were robust and could be used to identify compounds that inhibit Lmpdi reductase activity. Further evaluation of the selected compounds was performed using the Jurkat cell cytotoxicity assay as described. Only six compounds showed cytotoxic effect on cells with an ec 50 lower than 50 µm (table 1). this evaluation was carried out to investigate whether the cytotoxicity in Jurkat cells could constitute an efficient method to prioritize the hits detected in the primary screen, and thus it was not considered a selection step in this work.
several models have been used to evaluate antileishmanial activity of drugs on intracellular amastigotes. human peripheral blood-derived macrophages have been employed, but the supply of fresh macrophages is often limited. cell lines provide an unlimited source of uniform host cells. the human leukemia monocyte thp-1 cell line has been used as a successful model 
